New Funds for Pharma Sector Insights Firm ODAIA

In Canada, pharma sector predictive insights platform ODAIA has raised $25m in a Series B round of funding, which it will use to continue to evolve its platform and expand its team.

ODAIA's proprietary MAPTUAL platform offers near real-time and insights on the changes in the pharmaceutical marketplace. The firm's data-driven and AI-powered approaches are used to identify distinct population subsets and their healthcare providers, enabling marketers to gain an understanding of their market and then develop targeted campaigns. Insights available also include an understanding of the patients providers are treating, brand and market forecasts, target prioritization for call planning, and an understanding of the most effective channels to reach those targets.

New funding has been led by Threshold Ventures and Monograph Capital, with participation from Wittington Ventures and existing investors Flint Capital, BDC Capital's Women in Technology Venture Fund, StandUp Ventures and Graphite Ventures.

Philip Poulidis (pictured), CEO and co-founder of ODAIA, comments: 'Even in a challenging funding environment, our valued investors clearly recognized the significant problem we're solving for the pharmaceutical industry. With these funds, we'll continue to evolve our product and build out our team to ensure we're able to offer our existing and future life science brands the predictive tools needed for today's market, and tomorrow's.'

Web site: www.odaia.ai .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.